9.910EUR-1.05%Mkt Cap: 7.33B $P/E: 15.02Today
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates thr…
Industry Peers
Drug Manufacturers - GeneralKey Statistics
Company
Market Cap7.33B $
Enterprise Value19.63B $
Revenue (TTM)8.07B $
Gross Profit3.11B $
Net Income (TTM)436.96M $
Revenue/Share11.79 USD
Last Price9.910 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees25.3K
CountryES
SectorHealthcare
IndustryDrug Manufacturers - General
ISIN—
Valuation
P/E (Trailing)15.02
P/E (Forward)8.85
PEG0.24
EV/EBITDA10.98
EV/Revenue2.43
P/S0.92
P/B1.23
EPS (TTM)0.65
EPS (Forward)1.13
52W Range
8.43233% of range12.87
52W High12.87 EUR
52W Low8.432 EUR
Profitability
Gross Margin38.00%
Oper. Margin15.90%
EBITDA Margin22.17%
Profit Margin5.34%
ROE7.63%
ROA2.04%
Growth
Revenue Growth-0.90%
Earnings Growth32.90%
Cash Flow & Leverage
Operating CF1.14B $
CapEx (TTM)459.78M $
FCF Margin7.72%
FCF Yield8.49%
Net Debt9.59B $
Net Debt/EBITDA5.36
Balance Sheet
Debt/Equity1.81
Current Ratio2.37
Quick Ratio0.70
Book Value/Sh8.149 EUR
Cash/Share0.7890 EUR
Dividends
Fwd Div Rate0.0800 EUR
Trail. Div Rate0.0000 EUR
Div. Yield0.82%
5Y Avg Yield1.48%
Payout Ratio35.21%
Ex-Div DateJun 30, 2026
Pay Date—
Splits
Last Split2:1
Split DateJan 4, 2016
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)14.53 EUR
Upside (mean)+46.7%
Target Range6.300 EUR – 23.00 EUR
€6.300+46.7% to mean€23.00
# Analysts12
Ownership
Shares Out.422.36M
Float418.12M
Insiders31.19%
Institutions37.98%
Technical
SMA 509.467 (+4.7%)
SMA 2009.924 (-0.1%)
Beta1.19
S&P 52W Chg18.16%
Avg Vol (30d)1.35M
Avg Vol (10d)1.28M
Technical Indicators
RSI (14)55.4
MACD0.1346
MACD Signal0.1863
MACD Hist.-0.0517
BB Upper10.46 EUR
BB Middle10.05 EUR
BB Lower9.647 EUR
BB Width8.04%
ATR (14)0.2453 EUR
Vol Ratio (20d)0.50x